Teleflex’s subsidiary NeoTract has reported positive outcomes from an independent analysis of its UroLift System in UK patients with benign prostatic hyperplasia (BPH).
Conducted by Imperial College Health Partners, the study compared costs and patient outcomes between UroLift and the current standard of care, transurethral resection of the prostate (TURP).
Data revealed significant quality of life benefits with the UroLift System. It was further found that replacing TURP with UroLift can save around £27m in post-surgical complication costs for the National Health Service (NHS).
Unlike TURP, which requires hospitalisation of 2.7 days on average, UroLift System does not require overnight hospitalisation, general anaesthesia or post-operative catheterisation.
NHS Trust Leeds Teaching Hospitals urology consultant Oliver Kayes said: “The data analysis from this study sheds new light on the potential cost savings and improved patient outcomes associated with the prostatic urethral lift treatment.
“Post-surgery complications including urinary tract infections and blood transfusions are expensive complications of TURP and burdensome to men. The UroLift System offers men a new minimally invasive option that reduces the occurrence of these unpleasant side-effects.”
UroLift System is designed for the treatment of lower urinary tract symptoms caused due to BPH.
The system requires a minimally invasive transurethral outpatient procedure, during which patients receive permanent implants to alleviate prostate obstruction and directly open the urethra.
Teleflex Interventional Urology business unit president Dave Amerson said: “We are pleased to see this independent analysis highlighting the economic benefits to the NHS and improved quality of life British men may experience with the UroLift System treatment.”
Currently, the UroLift System is available in the US, Australia, Europe, South Korea, Mexico and Canada.